UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 30, 2018

 

 

REPLIMUNE GROUP, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Replimune Group, Inc.

18 Commerce Way, Woburn, MA 01801

(Address of principal executive offices, including Zip Code)

 

Registrant’s telephone number, including area code: (781) 995-2443

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  x

 

 

 

Item 8.01                                           Other Events.

 

On July 30, 2018, in connection with the previously disclosed initial public offering of the common stock of Replimune Group, Inc. (the “Company”), the Company issued and sold an additional 707,936 shares of its common stock to the underwriters for the offering at the initial public offering price of $15.00 per share, less underwriting discounts and commissions, representing the partial exercise of the underwriters’ option to purchase additional shares of the Company’s common stock. As of July 30, 2018, the Company has issued and sold an aggregate of 7,407,936 shares of its common stock in connection with its initial public offering, resulting in approximately $111.1 million in gross proceeds before underwriting discounts and commissions and other offering expenses.

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	REPLIMUNE GROUP, INC.
Date: July 30, 2018	By:	/s/ Robert Coffin
		Robert Coffin
		President and Chief Executive Officer

 

3